Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311
Debt
Debt-to-Equity RatioN/A
Current Ratio5.38
Quick Ratio5.38
Price-To-Earnings
Trailing P/E Ratio-5.78
Forward P/E Ratio-6.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$900,000.00
Price / Sales595.50
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book10.68
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-67,820,000.00
Net MarginsN/A
Return on Equity-106.34%
Return on Assets-84.63%
Miscellaneous
Employees37
Outstanding Shares30,980,000
Market Cap$540.52 million
Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics Inc (NASDAQ:STML) announced its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.02. The biopharmaceutical company had revenue of $0.50 million for the quarter. View Stemline Therapeutics' Earnings History.
When is Stemline Therapeutics' next earnings date?
What price target have analysts set for STML?
4 brokerages have issued 1-year price targets for Stemline Therapeutics' shares. Their predictions range from $22.00 to $38.00. On average, they anticipate Stemline Therapeutics' share price to reach $30.00 in the next year. This suggests a possible upside of 73.4% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.
What is the consensus analysts' recommendation for Stemline Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include Global Blood Therapeutics (GBT), Pacira Pharmaceuticals (PCRX), Cambrex (CBM), Arena Pharmaceuticals (ARNA), TESARO (TSRO), G1 Therapeutics (GTHX), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Mirati Therapeutics (MRTX), Puma Biotechnology (PBYI), Enanta Pharmaceuticals (ENTA), Myovant Sciences (MYOV) and Phibro Animal Health (PAHC).
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 52)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 58)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 53)
- Robert Francomano, Global Head of Commercial
Has Stemline Therapeutics been receiving favorable news coverage?
News stories about STML stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stemline Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Stemline Therapeutics.
Who are Stemline Therapeutics' major shareholders?
Stemline Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (6.43%), BlackRock Inc. (6.12%), Nexthera Capital LP (1.85%), Northern Trust Corp (1.23%), Point72 Asset Management L.P. (0.71%) and C WorldWide Group Holding A S (0.71%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.
Which institutional investors are selling Stemline Therapeutics stock?
STML stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Baker BROS. Advisors LP, Dimensional Fund Advisors LP, Point72 Asset Management L.P., Bank of New York Mellon Corp and Bank of New York Mellon Corp. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.
Which institutional investors are buying Stemline Therapeutics stock?
STML stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, C WorldWide Group Holding A S, Northern Trust Corp, Nexthera Capital LP, Los Angeles Capital Management & Equity Research Inc., Algert Global LLC and Rhumbline Advisers. View Insider Buying and Selling for Stemline Therapeutics.
How do I buy shares of Stemline Therapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $17.30.
How big of a company is Stemline Therapeutics?
Stemline Therapeutics has a market capitalization of $540.52 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Stemline Therapeutics employs 37 workers across the globe.
How can I contact Stemline Therapeutics?
Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
